Clinical Trial Update: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab [Phase 2]

View source ↗

Summary

A Phase 2 basket trial evaluating the combination of niraparib and dostarlimab across multiple cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Clear Cell Renal Cell Carcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Adenocarcinoma
• Head and Neck Cancer
• Pancreatic Ductal Adenocarcinoma
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)
• Zejula (Niraparib)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Urothelial Bladder Cancer, Gastric Adenocarcinoma | Phase 2 | Status: TERMINATED